Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis (RA-BioStop)

Ultrasound as Biomarker for Withdrawal of Biological DMARDs in Rheumatoid Arthritis

biological DMARDs may be stopped in Rheumatoid Arthritis (RA) patients treated with a combination of synthetic DMARD plus bDMARDs which are in persistent clinical remission. The research question of this study is, whether musculoskeletal sonography is a useful biomarker predicting a disease flare after cessation of bDMARD therapy.

Study Overview

• Status: Terminated
• Conditions: Rheumatoid Arthritis
• Intervention / Treatment: Drug: bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)

Detailed Description

Rheumatoid arthritis (RA) is the most common inflammatory joint disease. It is usually treated with synthetic and biologic disease modifying antirheumatic drugs (DMARDs). Up to 35% of patients can achieve clinical remission by the combination these therapies; however, there is considerable uncertainty regarding the management of patients once this clinical state is achieved. The discontinuation of biological agents in patients with persistent clinical remission may be beneficial for the patients and the health care system reducing the risks of long term adverse events and saving costs, respectively. Up to 60% of patients were reported to flare after cessation of anti-tumor necrosis factor alpha (TNF alpha) therapy despite continuation of synthetic DMARDs and up to now there exist no validated biomarkers that predict which patients will suffer a flare and which patients will remain in remission.

Sonography is more and more used as a biomarker in RA. Subclinical inflammation was previously associated with an increased risk for short term clinical relapse and structural deterioration.

The hypothesis of this prospective study is that ultrasound verified subclinical inflammation at the time of bDMARD withdrawal predicts a disease flare at week 16. The investigators plan to recruit RA-patients with persistent clinical remission according to SDAI and no current corticosteroid therapy. At baseline, bDMARD is stopped, synthetic DMARDs are continued. Patients undergo 9 study visits within 52 weeks. Ultrasound examinations of 14 joints as well as clinical and laboratory assessments with calculation of SDAI scores are performed at each visit. Patients are considered to have a disease flare if disease status changes from remission to active disease according to clinical scores. Patients with a flare of the disease are excluded from the active phase of the study and are treated according to current guidelines.

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Phase 4

Contacts and Locations

Study Locations

• Austria
  • Graz, Austria, 8036
    • Medical University Graz

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 90 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female patient ≥18 years and <90 years of age
• Classification of RA according to the ACR/EULAR 2010 criteria
• Persistent clinical remission as defined by the ACR/EULAR remission criteria for at least 6 months (documented at ≥2 visits)
• Written informed consent
• Current treatment with a single csDMARD or a combination of csDMARDs plus a stable dose and administration interval (for the last 6 months) of a TNF-alpha inhibitor
• No current systemic corticosteroid treatment (stopped for at least 4 weeks), no corticosteroid injection within 4 weeks
• Stable dose of NSAIDs for at least 1 week

Exclusion Criteria:

• • Current treatment with any investigational drug
• Current administration interval of the anti-TNF-alpha agent of >11 weeks
• Complete destruction of any joint to be investigated by sonography
• Current RA-related vasculitis or other active systemic (i.e. extraarticular) RA- manifestation with the exception of rheumatoid nodules
• Initial arthritis manifestations before the age of 17 years
• Planned surgery within the study period or history of surgery of any of the joints to be investigated clinically or by sonography
• Current severe medical illness requiring hospitalization
• Active infection or active malignancy at screening or infection during the past 4 weeks requiring (even temporary) discontinuation of the anti-TNF-alpha agent
• Pregnancy or lactation
• Inability of the patient to follow the protocol
• Current treatment with Rituximab (MabThera®)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: single arm ( bDMARD withdrawal ); single arm (bDMARD withdrawal)	Drug: bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); bDMARDS (etanercept, adalimumab, infliximab, certolizumab, golimumab, tocilizumab, abatacept) will be discontinued after baseline visit in all participants; Other Names: Remicade; Cimzia; Humira; Orencia; Enbrel; Simponi; Roactemra

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PD-signals predict relapse at week 16	Active inflammation at the time of bDMARD withdrawal indicated by the presence of a PD-score ≥1 in at least one joint out of a sonographic 14-joint count predicts relapse rate at week 16.	16 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PD-signals predict relapse at week 24	Active inflammation at the time of bDMARD withdrawal indicated by the presence of a PD-score ≥1 in at least one joint out of a sonographic 14-joint count predicts relapse rate at week 24	24 weeks
PD-signals predict relapse at week 52	Active inflammation at the time of bDMARD withdrawal indicated by the presence of a PD-score ≥1 in at least one joint out of a sonographic 14-joint count predicts relapse rate at week 52	52 weeks
PD-scores at time of relapse	RA-patients have higher PD-scores at time of a clinical flare compared to patients with maintained clinical remission	24 weeks
Increment of PD-scores precede flare	An increment of PD-scores at follow-up compared to baseline visits precedes a clinical flare	52 weeks
PD scores better predict a relapse than residual swollen joints	PD scores better predict a relapse at week 16, 24 and 52 than the presence of residual swollen joints	16, 24, 52 weeks
PD score at baseline correlates with relapse risk	The higher the PD score at baseline, the more likely is a relapse at weeks 16, 24 and/or 52	52 weeks
7. Patients converting from a rheumatoid factor (RF) positive to a RF negative status are less likely to experience a relapse at weeks 16, 24 and 52 than patients remaining seropositive	7. Patients converting from a rheumatoid factor (RF) positive to a RF negative status are less likely to experience a relapse at weeks 16, 24 and 52 than patients remaining seropositive	16, 24, 52 weeks
8. Blood biomarkers predict the time to flare after bDMARD withdrawal	8. Blood biomarkers predict the time to flare after bDMARD withdrawal
9. Blood biomarkers predict the time to re-achieve remission after flare and re-induction of bDMARD treatment	9. Blood biomarkers predict the time to re-achieve remission after flare and re-induction of bDMARD treatment
PD-scores and blood biomarkers at baseline predict radiographic progression at week 52	PD-scores and blood biomarkers at baseline predict radiographic progression at week 52	52

Collaborators and Investigators

• Sponsor: Medical University of Graz
• Investigators: Principal Investigator: Christian Dejaco, MD, PhD, Medical University of Graz

Study record dates

Study Major Dates

• Study Start: June 1, 2012
• Primary Completion (ACTUAL): November 19, 2020
• Study Completion (ACTUAL): November 19, 2020

Study Registration Dates

• First Submitted: May 16, 2012
• First Submitted That Met QC Criteria: May 17, 2012
• First Posted (ESTIMATE): May 18, 2012

Study Record Updates

• Last Update Posted (ACTUAL): December 1, 2020
• Last Update Submitted That Met QC Criteria: November 26, 2020
• Last Verified: November 1, 2020

More Information

Terms related to this study

• Keywords: rheumatoid arthritis; ultrasound; remission; biological DMARD
• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Arthritis; Arthritis, Rheumatoid; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Gastrointestinal Agents; Dermatologic Agents; Immune Checkpoint Inhibitors; Tumor Necrosis Factor Inhibitors; Etanercept; Adalimumab; Infliximab; Golimumab; Abatacept; Certolizumab Pegol
• Other Study ID Numbers: 2011-5; V2; 2011-005204-15 (EUDRACT_NUMBER)